Back to top

Tale of the Tape

Zacks Equity Research

Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%
September 22, 2016


Trades from $3

Dicerna Pharmaceuticals, Inc. (DRNA - Snapshot Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.11 to $3.85 in the past one-month time frame.

The company has seen no estimate revisions over the past 7 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Dicerna Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is DRNA going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>